x
- Home
- Diabetes Models
- In Vivo Models of Diabetes Mellitus
- In Vitro Models of Diabetes Mellitus
- Diabetes Drug R&D Services
- Therapeutic Areas
- Virtual Booth
- Company
Ace Therapeutics offers comprehensive antidiabetic drug discovery services, encompassing diverse mechanisms. Our services are tailored to meet the diverse needs of our clients at every stage of the drug discovery process, from identifying antidiabetic targets to screening drugs, testing drug activity, and conducting ADME and PK studies, all the way to identifying preclinical antidiabetic drug candidates.
Currently, multiple classes of antidiabetic medications are approved for clinical use, including insulin, biguanides, sulfonylureas, TZDs, meglitinides, α-glucosidase inhibitors, GLP-1 receptor agonists, dipeptidyl peptidase 4 (DPP4) inhibitors, and amylin analogs. These drugs have different mechanisms of action, including increasing insulin secretion by pancreatic β cells to increasing insulin sensitization in target tissues (e.g., muscle, fat) and inhibiting glucose absorption in the gastrointestinal tract. These drugs based on different mechanisms provide diverse treatment options for diabetes. Designing and developing antidiabetic drugs to target different mechanisms can lead to more effective diabetes management.
Fig. 1 Mechanisms of action of antidiabetic drugs. (Tyagi, A. et al., 2021)
We provide antidiabetic drug discovery services based on different mechanisms centred around improving insulin secretion, increasing insulin sensitivity, slowing carbohydrate uptake, promoting glucose excretion and mimicking the action of insulin. Our expertise and platform technologies enable us to provide our clients with the following antidiabetic drug discovery services:
Insulin secretagogues are a substance that stimulates the secretion of insulin by binding to the sulfonylurea receptor on pancreatic beta cells, leading to the closure of potassium channels and triggering the release of insulin. Our one-stop drug discovery services can develop promising insulin secretagogues for our clients.
Insulin analogs and sensitizers help to lower blood glucose levels, thereby improving diabetes treatment. Ace Therapeutics helps our clients develop novel Insulin analogs and sensitizers through a variety of strategies.
Starch blockers are a class of substances that inhibit alpha-amylase activity in the small intestine. By inhibiting alpha-amylase, starch blockers reduce the digestion of starch. Ace Therapeutics is committed to applying our expertise to help our clients develop novel starch blockers for more effective blood glucose management.
Ace Therapeutics leverages our strengths in diabetes and drug discovery to provide preclinical drug discovery and development services to clients worldwide. Our one-stop drug discovery services help clients obtain reliable data and support in the development of antidiabetic drugs based on different mechanisms. Our services include, but are not limited to, the following:
Ace Therapeutics offers mechanism-based antidiabetic drug discovery services that provide clients with flexible solutions to accelerate their drug development programs. Please do not hesitate to contact us for further information and we will be happy to provide you with more detailed details.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
